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Counterpoint: Selective Screening for
Gestational Diabetes Mellitus
G
estational diabetes mellitus (GDM),
deﬁnedascarbohydrateintolerance
ﬁrst diagnosed during pregnancy
(1), is a common medical complication of
pregnancy, affecting 1.1–14.3% of preg-
nantwomendependingontheethnicand
clinical characteristics of the population
andthediagnostictestemployed(2).Ever
sinceO’SullivanandMahan(3)published
theircriteriafordiagnosisofGDMusinga
100-g oral glucose tolerance test (GTT),
clinicians worldwide have been strug-
gling to determine whether screening for
GDM should be offered routinely in preg-
nancy and, if so, the optimal method of
screening.Therehavebeennoadequately
designed randomized controlled trials to
answer the question of whether screening
for GDM is both beneﬁcial and cost effec-
tive, leading to a wide variance in screen-
ing practices worldwide. The Australian
Carbohydrate Intolerance Study in Preg-
nant Women (ACHOIS), a multicenter
randomizedcontrolledtrialofGDMtreat-
ment versus routine prenatal care, found
a reduction in a composite of severe peri-
natal outcomes in the treatment group
compared with a control group receiving
routine prenatal care (4). Although it was
not a trial of screening, its results have
convinced many practitioners to adopt
some type of screening for GDM because
logically, in order to treat GDM (an
asymptomatic entity), one must ﬁrst
screenforit.Recently,theU.S.Preventive
Services Task Force (USPSTF), in an up-
date to its policy statement on screening
for GDM, recognized that treatment of
GDM after 24 weeks of gestation im-
proves some maternal and neonatal out-
comes but, conversely, also stated that
there is still insufﬁcient evidence to sup-
port screening of all pregnant women ei-
ther before or after 24 weeks of gestation
(5).Despitethis,mostcliniciansusesome
method of screening for GDM.
Ideally, the chosen screening proto-
col should identify subjects at maximal
risk of adverse pregnancy outcomes who
wouldmostbeneﬁtfromintensiﬁedman-
agement and surveillance, while freeing
the rest from the burden of excessive in-
terventions. Unfortunately, the policy of
universal or near-universal screening that
is recommended by numerous profes-
sional medical organizations (1,6–8) will
lead to the blanket labeling of a large
group of women as having GDM, without
differentiating between those at high and
those at low risk of pregnancy complica-
tions. It has very clearly been shown that
glucose intolerance in pregnancy is not a
threshold phenomenon but, rather, is
linked to several adverse pregnancy out-
comes along a continuum of measured
glucose values in both fasting and post-
prandial (or glucose challenge) states (9–
11).Notalloftheseoutcomesareofequal
clinical importance; to justify widespread
screening, one would prefer to show a re-
duction in serious outcomes such as peri-
natal death and permanent birth injury.
These are rare outcomes and, thus, are
difﬁcult to study. The best prospective
data on the effect of increasing levels of
glucose intolerance in pregnancy come
from the Toronto Tri-Hospital Gesta-
tional Diabetes Project (9) and have been
conﬁrmed by the recently published re-
sults of the Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study. The
data from the Toronto Tri-Hospital Ges-
tationalDiabetesProjectshowedagraded
increase in the risk of macrosomia and
preeclampsia, the need for phototherapy,
and maternal and neonatal length of stay.
The HAPO study largely conﬁrmed these
data and Pederson’s hypothesis (12),
showing a positive association between
plasma glucose values after a 75-g oral
GTT,birthweightabovethe90thpercen-
tile,andcordbloodC-peptidelevels(11).
Neither of these studies was able to iden-
tify clear outcome-based thresholds that
could lead to new clinically relevant diag-
nostic criteria for GDM.
This brings us to the current status in
2009 where we have evidence that treat-
mentofGDMreducessomeperinatalout-
comes without signiﬁcantly increasing
the cesarean section rate but still lack a
gold standard diagnostic or screening
test.InNorthAmerica,themostcommon
method of screening is a two-stage test
comprised of a 50-g oral glucose chal-
lenge test (GCT) at 24–28 weeks of ges-
tationfollowedbyeithera75-gora100-g
oral GTT for women who screen positive
on the GCT (13). Using a cutoff of 7.8
mmol/l (140 mg/dl) for the GCT, 14–
18%willtestpositiveandneedtoproceed
to the diagnostic test. The reported sensi-
tivity and speciﬁcity of this test strategy
are 80 and 90%, respectively, whereas
the positive and negative predictive val-
ues vary according to the prevalence of
GDMinthepopulationtested(14).Thus,
with this strategy some 20% of women
with GDM will remain undiagnosed even
withuniversalscreening.Inmanypartsof
Europe, a risk factor–based approach to
GDM screening is still the most common
approach (15–17). Common risk factors
can be found in Table 1. Overall, the per-
formance of risk factor–based screening
has been poor, with reported sensitivity
and speciﬁcity of 63 and 56%, respec-
tively (18). This poor performance is in
part due to the inability to apply historic
obstetric risk factors to women during
their ﬁrst pregnancy; thus, primiparas
who develop GDM will likely remain un-
diagnosed unless they develop macro-
somia, glycosuria, or polyhydramnios
during the index pregnancy. The prag-
maticutilityofapplyingriskfactor–based
screening will largely depend on the
frequency of these risk factors in the
screened population. For example, if the
screened population is mostly slim young
Caucasians, then many women will be
spared biochemical screening. On the
other hand, in heavier, older, multiethnic
obstetric populations, applying risk fac-
tor–basedscreeningwilllikelyleadtothe
majority of women undergoing biochem-
ical screening. Studies from North Amer-
ica have shown that using the American
Diabetes Association criteria for selective
screeningbasedonriskfactorswillleadto
some90%oftheobstetricpopulationstill
undergoing some form of biochemical
screening (19). This leaves us with the
question of whether it is possible to apply
a form of risk factor–based screening that
will spare the lower-risk population un-
necessary tests while maintaining the
performance of a universal screening
protocol. The answer is available from a
secondary analysis of data from the To-
ronto Tri-Hospital Gestational Diabetes
Project (20). The subject population in-
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tion group involving 3,131 women who
underwent a 50-g GCT at 26 weeks fol-
lowed by a 100-g oral GTT at 28 weeks of
gestation regardless of the results of the
screening test. Based on the derivation
group data, using multivariate analysis, a
simple clinical risk scoring system was
createdusingtheclinicalcharacteristicsof
maternal age, BMI, and race (Table 2).
The scoring system was then applied to
the validation group showing that the in-
cidence of GDM increased with increas-
ing clinical score values ranging from 0.9
in women who scored 1 to 18.7% in
womenwhoscored6.Ascreeningstrat-
egywasthendevelopedwherewomenwith
clinical scores 1 were not screened;
women with scores 2–3 were screened,
and the current cutoff of 7.8 mmol/l (140
mg/dl) was retained, whereas for women
with scores 4, two thresholds were ex-
amined:128and130mg/dl.Thisstrategy
was then applied to the validation group
with the results showing that although it
achievedsensitivityandspeciﬁcitysimilar
to those associated with universal screen-
ing, selective screening allowed 34.6% of
women to avoid screening altogether and
maintained a detection rate of 80%. If
we apply this simple strategy of asking a
woman her age and ethnicity and calcu-
lating her BMI to the most recent North
American birth statistics, 1.4 million
women in North America could avoid
routine screening for GDM (21). Al-
thoughsomecasesofGDMwillbemissed
inthelower-riskcategory,morecaseswill
be diagnosed in the higher-risk category
as a result of the lower thresholds applied
tothispopulation.Theeconomicanalysis
ofthisstrategyhasnotbeenevaluatedyet;
however, assuming that the impact of not
diagnosing GDM in the low-risk popula-
tion is minimal in terms of health care
USD, it is likely to result in savings of
close to 4 billion USD per year (22,23).
The main limitation of this method of
selective screening is that it is more com-
plex than universal screening and its im-
plementation adds an additional burden
tothehealthcareprovider.Butwhatisthe
actual burden? The data regarding age,
ethnicity, and BMI are collected routinely
at the ﬁrst prenatal visit. All the clinician
needs to do is to determine at that point
whether the patient is in the low-risk cat-
egory and thus can avoid screening. For
the remainder of patients who undergo a
GCT, the linkage between this clinical
dataset and the laboratory can easily be
incorporated into the laboratory report-
ing system, similar to what currently oc-
curs with prenatal screening for trisomy
21, allowing for the accurate application
of different glucose threshold values
based on the individual clinical scores.
In summary, there is still a wide gap
between screening practices in European
countries and North America. Regardless
of the screening method employed, the
decision whether to provide selective
screening or universal screening is largely
based on personal preference, expert
opinion,andclinicalguidelinesgiventhat
there is limited supporting evidence from
well-designed randomized clinical trials
supporting one method over the other.
Until better evidence is available, those
who employ universal screening need to
ask themselves whether it is justiﬁed to
subject all pregnant women to GDM
screening; although universal screening
will arguably identify more cases of GDM
in the low-risk population, these cases
might have less clinical signiﬁcance. By
applying selective screening strategies,
one can increase the detection of GDM in
thehigher-riskpopulation(increasedma-
ternal age and BMI), especially if lower
threshold criteria are applied to the GCT
in this select population. By doing this,
wewillbeabletofocusourresourceson
identifying cases where making the di-
agnosis of GDM will have an effect on
signiﬁcant perinatal outcomes, while
perhaps avoiding increased maternal
anxiety (24) and higher cesarean sec-
tion rates (25) in the low-risk
population.
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